Quality-of-life results used to endorse changes in standard of care for recurrent platinum-sensitive ovarian cancer.
Most women with ovarian cancer will suffer a recurrence. Unfortunately, although initial treatment can lead to undetectable disease, recurrent disease is often more challenging to control. As curative intent is less common after relapse, patients and doctors argue for improving quality-of-life (QoL) outcomes when therapies are selected. The article reviewed here discusses the QoL results of a trial in platinum-sensitive recurrent ovarian cancer where over 900 patients were randomized to the standard treatment (carboplatin and paclitaxel) versus carboplatin and pegylated liposomal doxorubicin. In the paper under evaluation, the standard of care is challenged based on a favorable clinical outcome in addition to QoL results in the experimental arm.
Division of Gynecologic Oncology, Creighton University School of Medicine at St Joseph's Hospital and Medical Center, Phoenix, AZ 85013, USA. dana.chase@chw.edu
Dana M
DM
Chase
Lari B
LB
Wenzel
Bradley J
BJ
Monk